Drug Profile


Alternative Names: OBE-001; Oxytocin antagonist - ObsEva

Latest Information Update: 24 Jan 2017

Price : $50

At a glance

  • Originator Merck Serono
  • Developer ObsEva
  • Class Oximes; Pyrrolidinones; Small molecules; Tocolytics
  • Mechanism of Action Oxytocin receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Female infertility; Preterm labour

Most Recent Events

  • 17 Jan 2017 ObsEva terminates a phase II trial in Preterm labour in Belgium, Germany, Poland, Spain, Switzerland and the UK(NCT02326142)
  • 01 Dec 2016 ObsEva completes the phase II IMPLANT trial for Female infertility in Belgium, Czech Republic, Denmark, Poland, Spain and the UK (NCT02310802)
  • 29 Dec 2015 Phase-II clinical trials in Preterm labour in Switzerland (PO) (NCT02326142)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top